This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA.
My last stop at Arrakis Therapeutics is with a company targeting RNA with smallmolecules. I was enticed by Arrakis’ founder Jen Petter to serve in one more operational role, leading the research group at Arrakis as the company launched as one of the first biotechs to target RNA with drug-like smallmolecules.
Unfortunately, in a Phase 3 clinical trial, treatment with remdesivir did not make a difference in mortality for Ebola virus disease patients. Without the stop sign, viral transcription no longer follows the correct order, which has a negative impact on viral proteinproduction,” says Fang.
Point-of-care peptide hormone production enabled by cell-free protein synthesis. Marine biofilm engineered to produce current in response to smallmolecules. Peroxisomal metabolic coupling improves fatty alcohol production from sole methanol in yeast. DeWinter MA. ACS Synthetic Biology. ACS Synthetic Biology.
Read Programming inactive RNA-binding smallmolecules into bioactive degraders. Read Maximizing proteinproduction by keeping cells at optimal secretory stress levels using real-time control approaches. Read Modular metabolic engineering and synthetic coculture strategies for the production of aromatic compounds in yeast.
Read Programming inactive RNA-binding smallmolecules into bioactive degraders. Read Maximizing proteinproduction by keeping cells at optimal secretory stress levels using real-time control approaches. Read Modular metabolic engineering and synthetic coculture strategies for the production of aromatic compounds in yeast.
The introduction of a nitro- group into a proteinmolecule is also implicated in different diseases including cardiovascular disease , lung disease, diabetes, cancer and some neurodegenerative conditions. It has been linked to the onset of several diseases and some examples are provided in the next section.
While small-molecule drugs continue to play a critical role in modern medicine, we are witnessing a shift toward the increasing development of amino acid-based therapeutics. Toxic peptides and proteins, particularly from the venoms of animals, are predicted to be a major source of next-generation peptide and protein-based drugs.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content